Safety of Intravenous Methylprednisolone in Refractory and Severe Pediatric Uveitis

References

• Gregory AC 2nd, Kempen JH, Daniel E, et al. Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study. Ophthalmology. 2013;120(1):186–192. doi:10.1016/j.ophtha.2012.07.052
   PubMed Web of Science ®Google Scholar
• Paivonsalo-Hietanen T, Tuominen J, Saari KM. Uveitis in children: population-based study in Finland. Acta Ophthalmol Scand. 2000;78(1):84–88.
   PubMedGoogle Scholar
• Edelsten C, Reddy MA, Stanford MR, Graham EM. Visual loss associated with pediatric uveitis in English primary and referral centers. Am J Ophthalmol. 2003;135(5):676–680.
   PubMed Web of Science ®Google Scholar
• Smith JA, Mackensen F, Sen HN, et al. Epidemiology and course of disease in childhood uveitis. Ophthalmology. 2009;116(8):1544–1551.
   PubMed Web of Science ®Google Scholar
• Rosenberg KD, Feuer WJ, Davis JL. Ocular complications of pediatric uveitis. Ophthalmology. 2004;111(12):2299–2306.
   PubMed Web of Science ®Google Scholar
• Burns CM. The History of Cortisone Discovery and Development. Rheum Dis Clin North Am. 2016;42(1):1–14, vii.
   PubMed Web of Science ®Google Scholar
• Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Care Res. 2019;71(6):717–734.
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res. 2016;68(1):1–25.
   PubMed Web of Science ®Google Scholar
• Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
   PubMed Web of Science ®Google Scholar
• Silver EM, Ochoa W. Glucocorticoid-Induced Myopathy in a Patient with Systemic Lupus Erythematosus (SLE): a Case Report and Review of the Literature. Am J Case Rep. 2018;19:277–283. doi:10.12659/AJCR.906377
   PubMed Web of Science ®Google Scholar
• Shimizu S, Naitoh I, Nakazawa T, et al. Correlation between long-term outcome and steroid therapy in type 1 autoimmune pancreatitis: relapse, malignancy and side effect of steroid. Scand J Gastroenterol. 2015;50(11):1411–1418.
   PubMed Web of Science ®Google Scholar
• Hodgins GE, Saltz SB, Gibbs EP, Gonzalez R, Regan J, Nemeroff C. Steroid-Induced Psychosis in the Pediatric Population: a New Case and Review of the Literature. J Child Adolesc Psychopharmacol. 2018;28(5):354–359.
   PubMed Web of Science ®Google Scholar
• Bonaventura A, Montecucco F. Steroid-induced hyperglycemia: an underdiagnosed problem or clinical inertia? A narrative review. Diabetes Res Clin Pract. 2018;139:203–220.
   PubMed Web of Science ®Google Scholar
• Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007;18(10):1319–1328.
   PubMed Web of Science ®Google Scholar
• Grossman A, Messerli FH, Grossman E. Drug induced hypertension–An unappreciated cause of secondary hypertension. Eur J Pharmacol. 2015;763(Pt A):15–22.
   PubMed Web of Science ®Google Scholar
• Suh SY, Kim JH, Kim SJ, Yu YS. Systemic steroid-induced cataracts in children: long-term changes in morphology and visual acuity. J AAPOS. 2013;17(4):371–373.
   PubMed Web of Science ®Google Scholar
• Singh JA, Hossain A, Kotb A, Wells G. Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis. BMC Med. 2016;14(1):137.
   PubMed Web of Science ®Google Scholar
• Emma F, Sesto A, Rizzoni G. Long-term linear growth of children with severe steroid-responsive nephrotic syndrome. Pediatr Nephrol. 2003;18(8):783–788.
   PubMed Web of Science ®Google Scholar
• Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum. 2000;43(8):1801–1808.
   PubMed Web of Science ®Google Scholar
• Ruiz-Irastorza G, Danza A, Perales I, et al. Prednisone in lupus nephritis: how much is enough? Autoimmun Rev. 2014;13(2):206–214.
   PubMed Web of Science ®Google Scholar
• Ruiz-Irastorza G, Ugarte A, Saint-Pastou Terrier C, et al. Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: an observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts. Autoimmun Rev. 2017;16(8):826–832.
   PubMed Web of Science ®Google Scholar
• Shahidi-Dadras M, Karami A, Toosy P, Shafiyan A. Pulse versus oral methylprednisolone therapy in pemphigus vulgaris. Arch Iran Med. 2007;10(1):1–6.
   PubMed Web of Science ®Google Scholar
• Ruiz-Arruza I, Lozano J, Cabezas-Rodriguez I, et al. Restrictive Use of Oral Glucocorticoids in Systemic Lupus Erythematosus and Prevention of Damage Without Worsening Long-Term Disease Control: an Observational Study. Arthritis Care Res. 2018;70(4):582–591.
   PubMed Web of Science ®Google Scholar
• Yong KL, Chng CL, Htoon HM, Lim LH, Seah LL. Safety Profile and Effects of Pulsed Methylprednisolone on Vital Signs in Thyroid Eye Disease. Int J Endocrinol. 2015;2015:457123.
   PubMed Web of Science ®Google Scholar
• Ravnborg M, Sorensen PS, Andersson M, et al. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Lancet Neurol. 2010;9(7):672–680.
   PubMed Web of Science ®Google Scholar
• Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992;326(9):581–588.
   PubMed Web of Science ®Google Scholar
• Charkoudian LD, Ying GS, Pujari SS, et al. High-dose intravenous corticosteroids for ocular inflammatory diseases. Ocul Immunol Inflamm. 2012;20(2):91–99.
   PubMed Web of Science ®Google Scholar
• Wakefield D, McCluskey P, Penny R. Intravenous pulse methylprednisolone therapy in severe inflammatory eye disease. Arch Ophthalmol. 1986;104(6):847–851.
   PubMedGoogle Scholar
• Wakefield D. Methylprednisolone pulse therapy in severe anterior uveitis. Aust N Z J Ophthalmol. 1985;13(4):411–415.
   PubMedGoogle Scholar
• McCluskey P, Wakefield D. Intravenous pulse methylprednisolone in scleritis. Arch Ophthalmol. 1987;105(6):793–797.
   PubMedGoogle Scholar
• Lendorf ME, Rasmussen AK, Fledelius HC, Feldt-Rasmussen U. Cardiovascular and cerebrovascular events in temporal relationship to intravenous glucocorticoid pulse therapy in patients with severe endocrine ophthalmopathy. Thyroid. 2009;19(12):1431–1432.
   PubMed Web of Science ®Google Scholar
• Marino M, Morabito E, Brunetto MR, Bartalena L, Pinchera A, Marocci C. Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves’ ophthalmopathy. Thyroid. 2004;14(5):403–406.
   PubMed Web of Science ®Google Scholar
• Marcocci C, Watt T, Altea MA, et al. Fatal and non-fatal adverse events of glucocorticoid therapy for Graves’ orbitopathy: a questionnaire survey among members of the European Thyroid Association. Eur J Endocrinol. 2012;166(2):247–253.
   PubMed Web of Science ®Google Scholar
• Chanouzas D, McGregor JAG, Nightingale P, et al. Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study. BMC Nephrol. 2019;20(1):58.
   PubMed Web of Science ®Google Scholar
• Kijima Y, Kamiya T, Suzuki A, Hirose O, Manabe H. A trial procedure to prevent aneurysm formation of the coronary arteries by steroid pulse therapy in Kawasaki disease. Jpn Circ J. 1982;46(11):1239–1242.
   PubMedGoogle Scholar
• Barron KS, Person DA, Brewer EJ Jr, Beale MG, Robson AM. Pulse methylprednisolone therapy in diffuse proliferative lupus nephritis. J Pediatr. 1982;101(1):137–141.
   PubMed Web of Science ®Google Scholar
• Kanno A, Hotta O, Yusa N, Taguma Y. Predictive factors of clinical outcome in patients with diffuse proliferative lupus nephritis treated early by intravenous methylprednisolone pulse therapy. Ren Fail. 2007;29(1):41–47.
   PubMed Web of Science ®Google Scholar
• Singh S, Chandrakasan S, Ahluwalia J, et al. Macrophage activation syndrome in children with systemic onset juvenile idiopathic arthritis: clinical experience from northwest India. Rheumatol Int. 2012;32(4):881–886.
   PubMed Web of Science ®Google Scholar
• Nakagishi Y, Shimizu M, Kasai K, Miyoshi M, Yachie A. Successful therapy of macrophage activation syndrome with dexamethasone palmitate. Mod Rheumatol. 2016;26(4):617–620.
   PubMed Web of Science ®Google Scholar
• Schnabel A, Unger E, Bruck N, et al. High-dose intravenous methylprednisolone in juvenile non-infectious uveitis: a retrospective analysis. Clin Immunol. 2020;211:108327.
   PubMed Web of Science ®Google Scholar
• Jongen PJ, Stavrakaki I, Voet B, et al. Patient-reported adverse effects of high-dose intravenous methylprednisolone treatment: a prospective web-based multi-center study in multiple sclerosis patients with a relapse. J Neurol. 2016;263(8):1641–1651.
   PubMed Web of Science ®Google Scholar
• Pentikainen PJ. Pharmacological aspects of corticosteroid pulse therapy. Scand J Rheumatol Suppl. 1984;54:6–9.
   PubMedGoogle Scholar
• Meyer PA, Watson PG, Franks W, Dubord P. ‘Pulsed’ immunosuppressive therapy in the treatment of immunologically induced corneal and scleral disease. Eye. 1987;1(Pt 4):487–495.
   PubMed Web of Science ®Google Scholar
• Kurki P. The effects of “pulse” corticosteroid therapy on the immune system. Scand J Rheumatol Suppl. 1984;54:13–15.
   PubMedGoogle Scholar
• Beck RW, Cleary PA, Trobe JD, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med. 1993;329(24):1764–1769.
   PubMed Web of Science ®Google Scholar
• Akaishi T, Takeshita T, Himori N, et al. Rapid Administration of High-Dose Intravenous Methylprednisolone Improves Visual Outcomes After Optic Neuritis in Patients With AQP4-IgG-Positive NMOSD. Front Neurol. 2020;11:932.
   PubMed Web of Science ®Google Scholar
• Tu X, Dong Y, Zhang H, Su Q. Corticosteroids for Graves’ Ophthalmopathy: systematic Review and Meta-Analysis. Biomed Res Int. 2018;2018:4845894.
   PubMed Web of Science ®Google Scholar
• Fukudome K, Fujimoto S, Sato Y, Kitamura K. Comparison of the effects of intravenous methylprednisolone pulse versus oral prednisolone therapies on the first attack of minimal-change nephrotic syndrome in adults. Nephrology. 2012;17(3):263–268.
   PubMed Web of Science ®Google Scholar
• van Staa TP, Abenhaim L, Cooper C, Zhang B, Leufkens HG. Public health impact of adverse bone effects of oral corticosteroids. Br J Clin Pharmacol. 2001;51(6):601–607.
   PubMed Web of Science ®Google Scholar
• Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med. 1994;154(1):97–101.
   PubMedGoogle Scholar
• Garbe E, LeLorier J, Boivin JF, Suissa S. Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids. Lancet. 1997;350(9083):979–982.
   PubMed Web of Science ®Google Scholar
• Decramer M, Lacquet LM, Fagard R, Rogiers P. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med. 1994;150(1):11–16.
   PubMed Web of Science ®Google Scholar
• Varas-Lorenzo C, Rodriguez LA, Maguire A, Castellsague J, Perez-Gutthann S. Use of oral corticosteroids and the risk of acute myocardial infarction. Atherosclerosis. 2007;192(2):376–383.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55(3):420–426.
   PubMed Web of Science ®Google Scholar
• Lopate G, Pestronk A, Al-Lozi M. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. Arch Neurol. 2005;62(2):249–254.
   PubMedGoogle Scholar
• Kapoor D, Sharma S, Garg D, et al. Intravenous Methylprednisolone Versus Oral Prednisolone for West Syndrome: a Randomized Open-Label Trial. Indian J Pediatr. 2021;1:65.
   Google Scholar
• Dasgupta B, Dolan AL, Panayi GS, Fernandes L. An initially double-blind controlled 96 week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica. Br J Rheumatol. 1998;37(2):189–195.
   PubMedGoogle Scholar
• Wollheim FA. Acute and long-term complications of corticosteroid pulse therapy. Scand J Rheumatol Suppl. 1984;54:27–32.
   PubMedGoogle Scholar
• Elzouki AY, Jaiswal OP. Long-term, small dose prednisone therapy in frequently relapsing nephrotic syndrome of childhood. Effect on remission, statural growth, obesity, and infection rate. Clin Pediatr. 1988;27(8):387–392.
   PubMed Web of Science ®Google Scholar
• Donatti TL, Koch VH, Fujimura MD, Okay Y. Growth in steroid-responsive nephrotic syndrome: a study of 85 pediatric patients. Pediatr Nephrol. 2003;18(8):789–795.
   PubMed Web of Science ®Google Scholar
• Madani A, Umar SU, Taghaodi R, Hajizadeh N, Rabbani A. The effect of long-term steroid therapy on linear growth of nephrotic children. Iran J Pediatr. 2011;21(1):21–27.
   PubMed Web of Science ®Google Scholar
• Polito C, Oporto MR, Totino SF, La Manna A, Di Toro R. Normal growth of nephrotic children during long-term alternate-day prednisone therapy. Acta Paediatr Scand. 1986;75(2):245–250.
   PubMed Web of Science ®Google Scholar
• Ruth EM, Kemper MJ, Leumann EP, Laube GF, Neuhaus TJ. Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome. J Pediatr. 2005;147(2):202–207.
   PubMed Web of Science ®Google Scholar